Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study | Zendy

Kohei Ogawa | Zendy; Ayumu Hosokawa | Zendy; Akira Ueda | Zendy; Seiko Saito | Zendy; Hiroshi Mihara | Zendy; Takayuki Ando | Zendy; Shinya Kajiura | Zendy; Mitsuhiro Terada | Zendy; Yuji Tsukioka | Zendy; Naoki Horikawa | Zendy; Takashi Kobayashi | Zendy; Masayuki NOTE | Zendy; Kunihiro SAWASAKI | Zendy; Junya Fukuoka | Zendy; Toshiro Sugiyama | Zendy

Open Access

Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study

Author(s) -

Kohei Ogawa,

Ayumu Hosokawa,

Akira Ueda,

Seiko Saito,

Hiroshi Mihara,

Takayuki Ando,

Shinya Kajiura,

Mitsuhiro Terada,

Yuji Tsukioka,

Naoki Horikawa,

Takashi Kobayashi,

Masayuki NOTE,

Kunihiro SAWASAKI,

Junya Fukuoka,

Toshiro Sugiyama

Publication year - 2012

Publication title -

gastroenterology research and practice

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.622

H-Index - 45

eISSN - 1687-630X

pISSN - 1687-6121

DOI - 10.1155/2012/640401

Subject(s) - irinotecan , medicine , cisplatin , mitomycin c , oncology , chemotherapy , cancer , surgery , colorectal cancer

Background . S-1 plus cisplatin has been established to be standard first-line chemotherapy for advanced gastric cancer in Japan. The optimal second-line treatment refractory to S-1 plus cisplatin remains unclear. Methods . We retrospectively studied the efficacy, toxicity, and survival of irinotecan plus mitomycin C in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin. Results . Twenty-four patients were studied. Prior chemotherapy was S-1 plus cisplatin in 15 patients, S-1 plus cisplatin and docetaxel in 8, and 5-fluorouracil plus cisplatin with radiotherapy in 1. The overall response rate was 17.4%. The median overall survival was 8.6 months, and the median progression-free survival was 3.6 months. Grade 3 or 4 toxicities included leukopenia (33%), neutropenia (50%), anemia (33%), thrombocytopenia (4%), anorexia (13%), diarrhea (4%), and febrile neutropenia (13%). Conclusion . A combination of irinotecan and mitomycin C is potentially effective in patients with advanced gastric cancer refractory to a fluoropyrimidine plus cisplatin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research